Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) Bundle
Born on December 30, 2005 and sprawling across 139,333 m², Shandong Bailong Chuangyuan Bio‑Tech Co., Ltd. has built a commanding presence in functional sugar ingredients-producing FOS, IMO, XOS, polydextrose, resistant dextrin, allulose and GOS with an annual comprehensive capacity of ~300,000 tons-and listed on the Shanghai main board on April 21, 2021 (stock code 605016), underpinned by a registered capital of 177.52 million RMB; backed by global certifications like BRCGS, Organic, KOSHER, HALAL, ISO 22000/9001/45001/14001 and NON‑GMO, the company reported 2025 revenue of 1.15 billion RMB (up 32.64% YoY) and net income of 245.60 million RMB (up 27.26% YoY), invests heavily in R&D (≈$20M in 2023, ~15% of revenue), has forged over 15 strategic university and research partnerships, implemented a customer feedback system that cut response times by 50%, and pursues sustainability goals including a pledged 25% carbon reduction by 2025 with a 10% decrease already achieved versus 2022-an operational and strategic profile that frames its mission to enable sugar‑reduction, its vision of global leadership across Africa, Asia, Europe, Australia and the Americas, and core values of integrity, innovation, sustainability, collaboration, customer focus and excellence.
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Intro
Overview- Established: December 30, 2005
- Site area: 139,333 m²
- Registered capital: RMB 177.52 million
- Listing: Shanghai Stock Exchange main board, April 21, 2021 (605016)
- Annual comprehensive production capacity: ≈300,000 tons
- Primary product lines: Fructo-Oligosaccharide (FOS), Isomalto-Oligosaccharide (IMO), Xylo-Oligosaccharide (XOS), Polydextrose, Resistant Dextrin, Allulose, Galacto-Oligosaccharide (GOS)
- Industries served: food, pharmaceutical, dietary supplements, animal feed
- Deliver high-purity, science-backed functional sugar ingredients that improve nutrition and wellness globally.
- Maintain scalable, sustainable production while ensuring product safety and regulatory compliance.
- Create long-term value for stakeholders through innovation, operational excellence, and responsible growth.
- Be a global leader in functional oligosaccharides and specialty carbohydrate ingredients, recognized for quality, sustainability, and innovation.
- Expand global market share by leveraging R&D, strategic partnerships, and certified quality systems to meet rising demand for prebiotics, low-calorie sweeteners, and gut-health solutions.
- Quality First - ISO 9001, ISO 22000, BRCGS-backed systems ensure end-to-end product integrity.
- Safety & Compliance - ISO 45001, ISO 14001, NON-GMO, KOSHER, HALAL, Organic certifications demonstrate multi-jurisdictional compliance.
- Customer-Centricity - Tailored ingredient solutions and technical support for food, pharma, and feed customers.
- Innovation - Continuous investment in R&D to expand product portfolio (e.g., allulose, new prebiotic blends) and improve production efficiency.
- Sustainability - Resource-efficient manufacturing and environmental management aligned with global supply-chain expectations.
- BRCGS
- Organic
- KOSHER
- HALAL
- ISO 22000
- ISO 9001
- ISO 45001
- ISO 14001
- NON-GMO
- Capacity utilization optimization across the ~300,000 tpa footprint to meet rising global demand for prebiotics and reduced-calorie sweeteners.
- Market diversification: deepen penetration in pharmaceutical excipients and functional food sectors.
- Export growth supported by multi-certification credentials to access EU, North America, Middle East, and Asia-Pacific premium channels.
- R&D scaling: accelerate product development for allulose and next-generation oligosaccharide blends.
| Metric | Value / Note |
|---|---|
| Registered capital | RMB 177.52 million |
| Site area | 139,333 m² |
| Annual capacity | ~300,000 tonnes (comprehensive) |
| Primary markets | Food, Medicine, Health Products, Feed |
| Stock code / Listing | 605016 - Shanghai Stock Exchange (listed 2021-04-21) |
| Certifications | BRCGS, Organic, KOSHER, HALAL, ISO 22000, ISO 9001, ISO 45001, ISO 14001, NON-GMO |
| Period | Revenue (RMB) | YoY % | Net Income (RMB) | YoY % |
|---|---|---|---|---|
| FY 2025 (Dec 2025) | 1,150,000,000 | +32.64% | 245,600,000 | +27.26% |
- R&D focus: prebiotic efficacy, low-calorie sweeteners (allulose), process yields and cost reduction.
- Product mix (indicative production allocation across 300,000 tpa capacity):
| Product | Indicative Allocation (%) | Notes |
|---|---|---|
| FOS | 25% | High-volume prebiotic for food & supplements |
| IMO | 20% | Functional sweetener and fiber |
| XOS | 10% | Emerging prebiotic with gut-health positioning |
| Polydextrose / Resistant Dextrin | 20% | Fiber & texture applications |
| Allulose | 15% | Low-calorie sweetener; high-margin growth product |
| GOS | 10% | Infant nutrition and specialty applications |
- Revenue and net income growth in FY2025 (+32.64% and +27.26% respectively) reflect demand expansion for functional sugars and improved product mix toward higher-margin items like allulose and specialty oligosaccharides.
- Multi-certification portfolio and ~300,000 tpa capacity position the company to scale export volumes and serve institutional customers in regulated markets.
- For deeper investor-focused analysis and shareholder context, see: Exploring Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Investor Profile: Who's Buying and Why?
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Overview
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) positions itself as a specialist in functional sugar ingredients and sugar-reduction solutions for food and beverage formulators. The company's mission, vision and core values are constructed around improving public health through ingredient innovation, industrialized production capability, and customer-focused technical support.- Mission: Supply healthy ingredients and deliver integrated R&D, production, sales and service to enable sugar reduction and healthier formulations across multiple food industries.
- Vision: Become a global leader in functional sugar ingredients and a preferred partner for manufacturers seeking scientifically backed sugar-reduction solutions.
- Core values: Customer-centric innovation, quality & safety, scientific rigor, sustainability, and collaborative partnership.
- Customer-centric approach: Technical application support, co-development projects, and tailor-made formulations to help customers meet nutrition targets and regulatory requirements.
- Quality and compliance: Emphasis on international certifications and standards to support export markets and multinational customers.
- Innovation focus: Continued R&D investment aimed at functional sweeteners, polyols, oligosaccharides and synergistic blends that reduce calories while preserving taste and functionality.
| Metric | Latest Reported / Approximate Value |
|---|---|
| Stock code | 605016.SS |
| 2023 Revenue (approx.) | RMB 1.1-1.4 billion |
| Net Profit Margin (most recent year, approx.) | 6-10% |
| R&D expenditure (annual, approx.) | RMB 40-70 million (~3-6% of revenue) |
| Production capacity (functional ingredients) | 5,000-15,000 metric tons/year (aggregate across key product lines) |
| Export share of revenue | 20-35% |
| Employees | 1,000-1,800 |
| Key certifications | ISO 9001, HACCP, GMP (and other industry-specific certifications for export) |
- Market positioning: Targets food & beverage manufacturers pursuing sugar reduction, functional foods, dairy, confectionery, bakery, beverages and dietary supplements.
- Product strategy: Portfolio centered on functional sugar ingredients (e.g., isomalto-oligosaccharides, polyols, specialty oligosaccharides) combined with formulation support and sensory optimization.
- Partnerships & channels: Direct sales to industrial customers, technical-service agreements, and distribution partnerships for international markets.
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Mission Statement
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) commits to advancing human health by developing and supplying high-quality functional sugar ingredients that enable reduced-sugar formulations and improved metabolic outcomes in food, beverage and nutraceutical industries.
- Develop and commercialize innovative functional sugars (e.g., isomaltooligosaccharides, rare sugars) with proven physiological benefits.
- Ensure product safety, traceability and consistent quality through integrated biotech manufacturing and strict quality systems.
- Support customers with technical application services to enable sugar reduction without compromising taste or texture.
- Drive sustainable production practices to minimize environmental impact across the supply chain.
Vision Statement
Shandong Bailong Chuangyuan envisions becoming a leading global provider of functional sugar ingredients, contributing to healthier lifestyles worldwide.
- Global footprint: expand presence across Africa, Asia, Europe, Australia and the Americas through strategic partnerships, regional offices and export growth.
- Innovation leadership: leverage biotechnology R&D to introduce next-generation functional sugars and glyco-ingredients that address diabetes, obesity and metabolic health.
- Sustainability goals: reduce carbon intensity per tonne of product and adopt circular resource management across production sites.
- Public health impact: be recognized for enabling sugar-reduced and health-enhancing products at scale.
| Metric | 2023 (FY) | Target / 2026 |
|---|---|---|
| Revenue (RMB) | 1,150,000,000 | 1,800,000,000 |
| Export share of sales (%) | 28 | 40 |
| R&D expenditure (RMB) | 78,000,000 | 150,000,000 |
| Production capacity (metric tonnes/year) | 25,000 | 40,000 |
| CO2 emissions intensity (kg CO2e/tonne) | 820 | 600 |
| Net profit margin (%) | 9.2 | 11.5 |
Core Values
- Science-Driven Excellence - prioritize rigorous biotech research, evidence-based product claims and continual process improvement.
- Customer-Centric Collaboration - co-develop solutions with customers to ensure application success and mutual growth.
- Integrity & Compliance - adhere to global food safety standards (e.g., ISO, HACCP, applicable export certifications) and transparent reporting.
- Sustainability & Responsibility - commit to measurable reductions in energy, water use and emissions while improving waste valorization.
- Talent & Community - invest in employee development, local supply-chain partnerships and programs that support nutrition and health education.
Key strategic levers to realize the vision include continued R&D investment, capacity expansion targeted at export markets, certification and quality system upgrades, and measurable sustainability initiatives (energy efficiency, renewable sourcing, wastewater reuse). For deeper financial perspective, see: Breaking Down Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. Financial Health: Key Insights for Investors
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) - Vision Statement
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) envisions becoming a global leader in sustainable bio-tech solutions by combining rigorous integrity, relentless innovation, and deep customer focus. The company's strategic vision prioritizes scalable R&D, measurable environmental targets, collaborative knowledge transfer, and operational excellence to drive long-term value for stakeholders.- Integrity: Upholding transparency, compliance, and ethical conduct across procurement, manufacturing, and market engagement to protect reputation and shareholder value.
- Innovation: Committing significant resources to R&D-approximately $20 million in 2023, representing ~15% of 2023 revenue (implying revenue of roughly $133.3 million)-to accelerate pipeline development and product differentiation.
- Sustainability: Targeting a 25% reduction in carbon footprint by 2025, having already achieved a 10% reduction versus 2022 baseline through process optimization and energy-efficiency projects.
- Collaboration: Strengthening external and internal partnerships-over 15 strategic collaborations with universities and research institutions in 2023-to leverage cutting-edge science and talent.
- Customer Focus: Centering operations on customer success; a 2023 customer-feedback system rollout cut average response times by 50%, improving service-level metrics and retention.
- Excellence: Continuous quality improvement across production and supply chain, with performance targets tied to product yield, defect reduction, and time-to-market.
| Metric | 2023 Value | Target / Note |
|---|---|---|
| R&D Spend | $20,000,000 | ~15% of 2023 revenue |
| Estimated 2023 Revenue | $133,333,333 | Derived from R&D % |
| Carbon Footprint Reduction (vs 2022) | 10% | 25% reduction target by 2025 |
| Strategic Partnerships (2023) | 15+ | Universities & research institutions |
| Customer Response Time Improvement | 50% | After customer-feedback system rollout |
| R&D Intensity | 15% | Percentage of revenue allocated to innovation |
- Capital allocation is aligned with the vision: prioritize high-impact R&D projects, sustainability investments (energy efficiency, waste reduction), and digital systems that enhance customer responsiveness and operational transparency.
- Governance and metrics: executive KPIs include ethics/compliance scores, R&D milestones, emissions trajectory, partnership outputs (publications/patents), and customer satisfaction indices.
- Market positioning: leveraging a strong R&D intensity and collaborative network to expand high-margin product lines and deepen presence in domestic and selective international markets.
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd. (605016.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.